Willis C. Lee - Feb 26, 2024 Form 4 Insider Report for Emmaus Life Sciences, Inc. (EMMA)

Role: Co-President & COO, Director
Signature: Willis C. Lee
Stock symbol: EMMA
Transactions as of: Feb 26, 2024
Transactions value $: $14,694
Form type: 4
Date filed: 2/29/2024, 06:11 PM
Previous filing: Feb 5, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EMMA	Common stock, $0.001 par value	Purchase	$1.58K	+13.2K	+29.86%	$0.12	57.4K	Feb 26, 2024	By Fidelity Roth IRA FBO Willis C. Lee	F1
transaction	EMMA	Common stock, $0.001 par value	Purchase	$1.3K	+10K	+17.42%	$0.13	67.4K	Feb 27, 2024	By Fidelity Roth IRA FBO Willis C. Lee
transaction	EMMA	Common stock, $0.001 par value	Purchase	$1.8K	+15K	+22.26%	$0.12	82.4K	Feb 28, 2024	By Fidelity Roth IRA FBO Willis C. Lee	F2
transaction	EMMA	Common stock, $0.001 par value	Purchase	$10K	+77K	+93.45%	$0.13	159K	Feb 29, 2024	By Fidelity Roth IRA FBO Willis C. Lee
holding	EMMA	Common stock, $0.001 par value						395K	Feb 26, 2024	Direct
holding	EMMA	Common stock, $0.001 par value						241K	Feb 26, 2024	By Fidelity Traditional IRA FBO Willis C. Lee

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4.
F2	The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive.

Content

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4.

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive.